<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and staging of testicular germ cell tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and staging of testicular germ cell tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and staging of testicular germ cell tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Graeme S Steele, MBBCh, FCS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Dror Michaelson, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seth P Lerner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Testicular cancer is the most common solid malignancy affecting males between the ages of 15 and 35, although it accounts for only 1 percent of all cancers in males [<a href="#rid1">1</a>]. Testicular cancer is also one of the most curable of solid neoplasms because of remarkable treatment advances, with five-year survival rates of approximately 95 percent [<a href="#rid2">2</a>].</p><p>Germ cell tumors (GCTs) account for 95 percent of testicular cancers  (<a class="graphic graphic_table graphicRef81626" href="/d/graphic/81626.html" rel="external">table 1</a>). They may consist of one predominant histologic pattern or represent a mix of multiple histologic types. For treatment purposes, two broad categories of testis tumors are recognized: pure seminoma (no nonseminomatous elements present) and all others, which together are termed nonseminomatous germ cell tumors (NSGCTs). In most series, the ratio of seminoma to NSGCT is approximately one.</p><p>The clinical manifestations, diagnosis, and staging of testicular cancer will be presented here. Optimal therapy, which varies with the stage of disease, is discussed separately. (See  <a class="medical medical_review" href="/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>.) </p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Testicular tumors usually present as a nodule or painless swelling of one testicle, which may be noted incidentally by the patient or by his sexual partner [<a href="#rid3">3</a>]. Occasionally, a male with a previously small atrophic testis will note enlargement. Approximately 30 to 40 percent of patients complain of a dull ache or heavy sensation in the lower abdomen, perianal area, or scrotum, while acute pain is the presenting symptom in 10 percent.</p><p>The presenting manifestations of testicular cancer are attributable to metastatic disease in approximately 10 percent of patients. Symptoms vary with the site of metastasis:</p><p class="bulletIndent1"><span class="glyph">●</span>A neck mass (supraclavicular lymph node metastasis)</p><p class="bulletIndent1"><span class="glyph">●</span>Cough or dyspnea (pulmonary metastasis)</p><p class="bulletIndent1"><span class="glyph">●</span>Anorexia, nausea, vomiting, or gastrointestinal hemorrhage (retroduodenal metastasis)</p><p class="bulletIndent1"><span class="glyph">●</span>Lumbar back pain (bulky retroperitoneal disease involving the psoas muscle or nerve roots)</p><p class="bulletIndent1"><span class="glyph">●</span>Bone pain (skeletal metastasis)</p><p class="bulletIndent1"><span class="glyph">●</span>Central or peripheral nervous system symptoms (cerebral, spinal cord, or peripheral root involvement)</p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral or bilateral lower extremity swelling (iliac or caval venous obstruction or thrombosis)</p><p></p><p>Gynecomastia, which occurs in approximately 5 percent of males with testicular germ cell tumors, is a systemic endocrine manifestation of these neoplasms [<a href="#rid4">4</a>]. It also occurs in 20 to 30 percent of patients with the less common (2 percent of testicular tumors) Leydig cell tumors of the testes [<a href="#rid5">5</a>]. These tumors are found in 6- to 10-year-old boys who present with precocious puberty and in 26- to 35-year-old males who present with a testicular mass, gynecomastia, impotence, and loss of libido. (See  <a class="medical medical_review" href="/d/html/2972.html" rel="external">"Testicular sex cord stromal tumors"</a>.)</p><p>Gynecomastia is usually associated with production of human chorionic gonadotropin (hCG) by foci of choriocarcinoma or trophoblastic cells in the tumor. However, the relationship between gynecomastia, testicular tumor morphology, and endocrine abnormalities remains incompletely defined. In individual patients, gynecomastia may or may not be associated with elevated serum concentrations of hCG, human chorionic somatomammotropin, prolactin, estrogens, or androgens. (See  <a class="medical medical_review" href="/d/html/7466.html" rel="external">"Epidemiology, pathophysiology, and causes of gynecomastia"</a> and  <a class="medical medical_review" href="/d/html/7476.html" rel="external">"Clinical features, diagnosis, and evaluation of gynecomastia in adults"</a>.)</p><p>Patients with marked overproduction of hCG can develop another endocrine complication, paraneoplastic hyperthyroidism [<a href="#rid6">6</a>]. Thyroid-stimulating hormone and hCG have a common alpha subunit and a beta subunit with considerable homology. As a result, hCG has weak thyroid-stimulating activity. (See  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'hCG and thyroid function'</a> and  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism", section on 'Trophoblastic disease and germ cell tumors'</a>.)</p><p>Patients with testicular cancer may rarely develop a paraneoplastic limbic encephalitis. Most of these patients have anti-Ma2 (also called anti-Ta) antibodies [<a href="#rid7">7</a>]. The Ma2 antigen is selectively expressed in the neuronal nucleoli of normal brain tissue and the testicular tumor of the patient. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Ma2-associated encephalitis'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Testicular examination</span><span class="headingEndMark"> — </span>Physical examination of the testes should begin with bimanual examination of the scrotal contents, starting with the normal contralateral testis. This permits the examiner to appreciate the relative size, contour, and consistency of the normal testis as a baseline for comparison with the suspected gonad. The testis should be carefully palpated between the thumb and first two fingers of the examining hand.</p><p>The normal gonad is homogeneous in consistency, freely movable, and separable from the epididymis. Any firm, hard, or fixed area within the substance of the tunica albuginea should be considered suspicious until proven otherwise. Further evaluation of the affected side should be directed toward possible involvement of the spermatic cord, scrotal investments, or skin.</p><p>Testicular tumors tend to remain ovoid, being limited by the tough investing tunica albuginea. However, spread to the epididymis or spermatic cord occurs in 10 to 15 percent of patients. In general, a seminoma tends to expand within the testis as a painless, rubbery enlargement, while an embryonal carcinoma or teratocarcinoma forms an irregular mass with indiscrete borders. However, this distinction is not always easily appreciated.</p><p>A hydrocele may be present and can make evaluation of a suspected testicular tumor more difficult. In such cases, ultrasonography of the scrotum is a rapid, reliable technique to exclude a hydrocele or epididymitis; it is indicated in any male with a suspected testicular tumor. (See <a class="local">'Scrotal ultrasound'</a> below.)</p><p>Physical examination should also include palpation of the abdomen for evidence of nodal disease or visceral involvement. Routine assessment of the supraclavicular lymph nodes may reveal adenopathy in males with advanced disease. Examination of the chest may disclose gynecomastia or raise suspicion for thoracic involvement.</p><p class="headingAnchor" id="H137129371"><span class="h3">Cryptorchidism</span><span class="headingEndMark"> — </span>Males with a history of cryptorchidism and prior orchiopexy are at increased risk for testicular cancer in both testes (greater in the undescended one), although the magnitude of increased risk compared with males in the general population is poorly quantified. Regardless, testicular self-examination is an important part of the routine evaluation. Because of the rarity of such tumors, surveillance scrotal ultrasound (in the absence of clinical exam findings) is not indicated. (See  <a class="medical medical_review" href="/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer", section on 'Cryptorchidism'</a> and  <a class="medical medical_review" href="/d/html/87856.html" rel="external">"Undescended testes (cryptorchidism) in children: Management", section on 'Long-term follow-up'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>In any male with a solid, firm mass within the testis, testicular cancer must be the considered diagnosis until proven otherwise. Prompt diagnosis and treatment of testicular cancer provides the best opportunity for cure. Nevertheless, both patient and clinician factors often contribute to a delay in diagnosis. Painless scrotal masses are sometimes ignored, while testicular cancers presenting with scrotal pain are often treated as epididymitis.</p><p>The differential diagnosis of a testicular mass includes testicular torsion, epididymitis, or epididymo-orchitis. Less common problems include hydrocele, varicocele, hernia, hematoma, spermatocele, or syphilitic gumma. In patients in whom the diagnosis is unclear or in whom a hydrocele precludes adequate examination, imaging studies are an important second step in determining the cause. (See  <a class="medical medical_review" href="/d/html/6873.html" rel="external">"Acute scrotal pain in adults"</a>.)</p><p>The diagnostic evaluation of males with suspected testicular cancer includes scrotal ultrasound followed by radiographic testing, measurement of serum tumor markers, radical inguinal orchiectomy, and in some cases, retroperitoneal lymph node dissection (RPLND). The results are used to determine the histologic type and extent of disease, and to guide therapy. Testicular biopsy is not performed as part of the evaluation due to concern that it may result in tumor seeding into the scrotal sac or metastatic spread of tumor into the inguinal nodes.</p><p>In addition, since the vast majority of these patients are young males, consideration should be given to fertility issues and sperm cryopreservation during the initial diagnostic evaluation. If possible, a baseline sperm count and sperm banking should be performed prior to the radiographic diagnostic evaluation in order to avoid radiation exposure of the sperm. (See <a class="local">'Cryopreservation of sperm'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h2">Scrotal ultrasound</span><span class="headingEndMark"> — </span>Bilateral scrotal ultrasound can distinguish intrinsic from extrinsic testicular lesions with a high degree of accuracy and can detect intratesticular lesions as small as 1 to 2 mm in diameter. In males with testicular masses, scrotal ultrasound has become an extension of the physical examination, but it should never be considered a substitute for the latter.</p><p>A cystic or fluid-filled mass is unlikely to represent malignancy. By comparison, seminomas appear as well-defined hypoechoic lesions without cystic areas, while nonseminomatous germ cell tumors (NSGCTs) are typically inhomogeneous with calcifications, cystic areas, and indistinct margins [<a href="#rid8">8,9</a>]. However, this distinction is not always apparent; in one series for example, the radiologist's interpretation of the type of tumor was correct in only 70 percent of cases [<a href="#rid9">9</a>]. Even magnetic resonance imaging (MRI) does not improve the specificity [<a href="#rid10">10</a>].</p><p>Another limitation is that because the tunica albuginea is difficult to discern by ultrasonography, local tumor staging has proved to be unreliable with this technique [<a href="#rid8">8,9</a>]. In the above report, tumor staging was accurate in 44 percent of seminomas and only 8 percent of nonseminomatous tumors [<a href="#rid9">9</a>]. For these reasons, scrotal ultrasound cannot replace radical inguinal orchiectomy for the determination of histology and stage.</p><p>The widespread use of scrotal ultrasound in the evaluation of male infertility occasionally leads to the diagnosis of an incidental nonpalpable testicular mass [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/7453.html" rel="external">"Approach to the male with infertility"</a>.)</p><p>In the largest series, 46 asymptomatic lesions smaller than 10 mm were identified in 4418 males evaluated for infertility [<a href="#rid11">11</a>]. The majority of the males did not undergo surgery and were followed with active surveillance and serial ultrasound. Among the eight patients who either chose surgery or who had surgery because of progressive enlargement of the lesion, one seminoma and two Leydig cell tumors were identified. The remaining five patients had benign lesions. The authors concluded that ultrasound surveillance for small, incidentally discovered testicular masses is a safe and appropriate alternative to surgery. For those males with an incidentally detected testicular mass (and normal serum tumor markers) who choose to undergo surgery, less-radical surgery (ie, excisional biopsy), rather than orchiectomy, is appropriate [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H3275416884"><span class="h3">Microlithiasis</span><span class="headingEndMark"> — </span>Testicular ultrasonography identifies patients with microlithiasis, defined as five or more echogenic 1 to 3 mm foci in a single cross-sectional ultrasound image. Retrospective cohort studies have demonstrated a strong association between microlithiasis and testicular cancer, both in adult and pediatric populations [<a href="#rid15">15,16</a>]. However, a causal link is unlikely as ultrasound surveillance of patients with microlithiasis with no clinical risk factors has not shown an increased incidence of cancer [<a href="#rid17">17</a>]. Consequently, patients with microlithiasis and otherwise normal ultrasound findings do not require further imaging, although they should be instructed in testicular self-examination [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H2682230796"><span class="h2">Imaging studies</span></p><p class="headingAnchor" id="H8"><span class="h3">CT scan</span><span class="headingEndMark"> — </span>A high-resolution computed tomography (CT) scan of the abdomen and pelvis, and a chest radiograph are generally performed [<a href="#rid3">3</a>]. Chest CT is recommended if the chest radiograph is abnormal or if metastatic disease involving the thorax is strongly suspected.</p><p>Regional metastases first appear in the retroperitoneal lymph nodes. Although CT is the imaging modality of choice to evaluate the retroperitoneum, false-negative rates as high as 44 percent have been described [<a href="#rid19">19</a>]. Occult micrometastases are responsible for most of these false negatives, as evidenced by a retroperitoneal relapse rate of 20 to 25 percent in males with clinical stage I disease who do not undergo RPLND [<a href="#rid20">20-22</a>].</p><p>The utility of the staging CT scan is also dependent on the cutoff value used to define an abnormal node. Most institutions use a 10 mm cutoff (measurement based upon the short axis in the transverse plane) to define pathologic adenopathy. Higher cutoffs (greater than 15 mm) yield higher false-negative rates, while lower cutoffs (less than 5 mm) may result in some patients undergoing unnecessary therapeutic RPLND [<a href="#rid23">23</a>] (see  <a class="medical medical_review" href="/d/html/2992.html" rel="external">"Retroperitoneal lymph node dissection for early-stage testicular germ cell tumors"</a>). A more exacting method to evaluate lymph node enlargement utilizes craniocaudal measurement of lymph nodes in the suspected landing site. Above 10 mm, for every 3 mm increase in craniocaudal length in patients with nonseminomatous tumors, the risk of relapse increased by 52 percent [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H137129438"><span class="h3">MRI</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) of the abdomen and pelvis or scrotum usually adds little to the information obtained by CT scan and ultrasound [<a href="#rid10">10</a>]. MRI of the brain is performed if brain metastases are suspected. Bone radionuclide scan is rarely indicated.</p><p class="headingAnchor" id="H9"><span class="h3">Is there a role for PET imaging?</span><span class="headingEndMark"> — </span>Positron emission tomography (PET) scan is of limited utility in the initial staging of patients with testicular germ cell tumors (GCTs) [<a href="#rid25">25,26</a>] because of the frequent occurrence of false-negative results:</p><p class="bulletIndent1"><span class="glyph">●</span>The utility of PET as compared with CT as an initial staging modality for the retroperitoneum was studied in a German study of 72 males, all of whom underwent subsequent RPLND for clinical stage I or II NSGCT [<a href="#rid25">25</a>]. In this study, correct nodal staging was achieved in more patients by PET compared to CT (83 versus 71 percent), and the positive predictive value was also higher with PET (95 versus 87 percent). However, false-negative results with PET-CT were still a problem, with a negative predictive value that was only modestly higher than that achieved by CT (78 versus 67 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results were seen in a subsequent study in 111 patients with clinical stage I NSGCT that used the negative results of PET to select patients for surveillance [<a href="#rid26">26</a>]. Of the 87 patients with a negative PET who were managed with surveillance, 33 (38 percent) relapsed within one year.</p><p></p><p>PET scanning is more commonly used for the evaluation of posttherapy residual masses than for initial diagnostic evaluation. (See  <a class="medical medical_review" href="/d/html/2990.html" rel="external">"Treatment of stage II seminoma", section on 'Posttherapy residual masses'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Serum tumor markers</span><span class="headingEndMark"> — </span>In a male suspected of having testicular cancer, blood should be obtained for a chemistry profile, a complete blood count, and serum tumor markers. Three serum tumor markers have established roles in testicular cancer: alpha-fetoprotein (AFP), the beta subunit of human chorionic gonadotropin (beta-hCG; since the alpha subunit is common to several pituitary hormones), and lactate dehydrogenase (LDH). Serum levels of AFP and/or beta-hCG are elevated in 80 to 85 percent of males with NSGCTs, even when nonmetastatic. By contrast, serum beta-hCG is elevated in less than 20 percent of testicular seminomas, and AFP is not elevated in pure seminomas. (See  <a class="medical medical_review" href="/d/html/2995.html" rel="external">"Serum tumor markers in testicular germ cell tumors"</a>.)</p><p>Neither serum beta-hCG nor AFP, alone or in combination, is sufficiently sensitive or specific to establish the diagnosis of testicular cancer in the absence of histologic confirmation. Marked elevations in these markers are rarely found in males, except in GCTs.</p><p class="bulletIndent1"><span class="glyph">●</span>Serum beta-hCG concentrations above 10,000 milli-international units/mL occur only in GCTs, the rare patient with trophoblastic differentiation of a primary lung or gastric cancer, or in females, pregnancy or gestational trophoblastic disease [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/7868.html" rel="external">"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes"</a> and  <a class="medical medical_review" href="/d/html/3243.html" rel="external">"Hydatidiform mole: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum AFP concentrations above 10,000 ng/mL occur almost exclusively in GCTs and hepatocellular carcinoma. (See  <a class="medical medical_review" href="/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma"</a>.)</p><p></p><p>These observations are especially pertinent for the patient with a suspected extragonadal GCT. Elevated serum tumor markers can be used to make the diagnosis if a biopsy is not feasible or will compromise a patient with compatible clinical features or if biopsy reveals poorly differentiated carcinoma. (See  <a class="medical medical_review" href="/d/html/4875.html" rel="external">"Poorly differentiated cancer from an unknown primary site", section on 'Extragonadal germ cell tumors'</a> and  <a class="medical medical_review" href="/d/html/4875.html" rel="external">"Poorly differentiated cancer from an unknown primary site", section on 'Clinical evaluation'</a>.)</p><p>Although serum tumor markers are helpful at the time of initial diagnosis of testicular cancer and for prognostication, their main utility is for subsequent follow-up of disease status after primary treatment. (See  <a class="medical medical_review" href="/d/html/2995.html" rel="external">"Serum tumor markers in testicular germ cell tumors"</a>.)</p><p>Studies have identified noncoding micro RNAs, the miR-371-373 cluster in particular, as a potential emerging tumor marker for both seminomas and NSGCTs [<a href="#rid28">28</a>]. </p><p class="headingAnchor" id="H11"><span class="h2">Radical inguinal orchiectomy</span><span class="headingEndMark"> — </span>A radical inguinal orchiectomy should be performed to permit histologic evaluation of the primary tumor and to provide local tumor control. Neither scrotal ultrasound, as mentioned above, nor serum tumor markers are sufficiently accurate to replace radical inguinal orchiectomy. (See  <a class="medical medical_review" href="/d/html/2986.html" rel="external">"Radical inguinal orchiectomy for testicular germ cell tumors", section on 'Scrotal violation'</a>.)</p><p class="headingAnchor" id="H352309658"><span class="h2">Contralateral testicular biopsy</span><span class="headingEndMark"> — </span>The role of contralateral testicular biopsy at the time of radical orchiectomy in a clinically normal testis is controversial. Testicular germ cell neoplasia in situ (GCNIS), a precursor for GCT, is present in 2 to 5 percent of males with GCTs [<a href="#rid29">29-31</a>]. (See  <a class="medical medical_review" href="/d/html/3003.html" rel="external">"Testicular germ cell neoplasia in situ"</a>.)</p><p>In North America, biopsy is not recommended, but instead, careful surveillance of the contralateral testis is advocated. By contrast, many European groups suggest biopsy, particularly in patients considered at increased risk of GCNIS (eg, cryptorchidism) [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Retroperitoneal lymph node dissection</span><span class="headingEndMark"> — </span>RPLND is the only reliable method to identify nodal micrometastases given the high false-negative rate with CT scan (see <a class="local">'CT scan'</a> above). It is also the gold standard for providing accurate pathologic staging of the retroperitoneum. Both the number and size of involved retroperitoneal lymph nodes have prognostic importance. (See  <a class="medical medical_review" href="/d/html/2992.html" rel="external">"Retroperitoneal lymph node dissection for early-stage testicular germ cell tumors"</a>.)</p><p>Following radiographic evaluation of the retroperitoneum and radical inguinal orchiectomy, a subset of patients with low-stage NSGCT (T1-3,N0-2,M0, see below) should be considered candidates for a surgical staging RPLND. By comparison, primary chemotherapy is the treatment of choice for patients with stage III disease or high-volume stage II disease; in such patients, RPLND is reserved for those with postchemotherapy residual disease (see  <a class="medical medical_review" href="/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>). Surveillance is an appropriate option for males with clinical stage I testicular cancer, especially those with limited risk factors, such as a minimal embryonal cell component and the absence of lymphovascular invasion. (See  <a class="medical medical_review" href="/d/html/2950.html" rel="external">"Surveillance for stage I testicular germ cell tumors following orchiectomy"</a>.)</p><p class="headingAnchor" id="H607300785"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>The results of clinical and radiographic evaluation are used to assign a clinical stage in order to estimate prognosis and guide therapy. Testicular cancer is staged using the eighth (2017) tumor, node, metastasis (TNM) staging system developed jointly by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC), which applies to both seminomas and nonseminomatous germ cell tumors (NSGCTs) [<a href="#rid33">33</a>]. In the TNM system, assessments of the primary tumor (T), lymph nodes (N), and distant metastases (M) are combined with serum tumor marker values (S) for the beta subunit of human chorionic gonadotropin (beta-hCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) to define prognostic stage groups from I to III  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/d/graphic/110731.html" rel="external">table 2A-B</a>). </p><p>It is important to note that for the purposes of TNM staging, the serum tumor markers should be assessed as S0 to S3 only <strong>after</strong> orchiectomy has been completed. (See  <a class="medical medical_review" href="/d/html/2986.html" rel="external">"Radical inguinal orchiectomy for testicular germ cell tumors", section on 'Serum tumor markers'</a>.)</p><p>Compared with NSGCTs, pure seminomas are more likely to be localized to the testis at presentation. Approximately 80 percent of males with seminomas present with stage I disease (limited to the testicle), while 15 percent have stage II disease (limited to the retroperitoneal nodes). (See  <a class="medical medical_review" href="/d/html/2993.html" rel="external">"Treatment of stage I seminoma"</a>.)</p><p>For males who present with advanced disease, numerous staging and prognostic systems have been proposed to separate different prognostic subgroups, based primarily on single-institution experience [<a href="#rid34">34-38</a>]. In 1997, consensus was reached on a uniform, validated prognostic model by the International Germ Cell Cancer Collaborative Group (IGCCCG). The classification system is discussed separately [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Definition of risk'</a>.)</p><p>Because of the availability of serum tumor markers and the predictable metastatic pattern of testicular cancer, most experts do not require a confirmatory biopsy of suspected disease as part of the staging procedure. Biopsies of suspected disease should only be performed in unusual situations, such as in patients who present with imaging-detected masses without elevated tumor markers, or the presence of disease in atypical locations (eg, bone [<a href="#rid40">40</a>]). If patients have evidence of advanced disease suggested by imaging and/or elevated tumor markers, definitive treatment is recommended. (See  <a class="medical medical_review" href="/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">CRYOPRESERVATION OF SPERM</span><span class="headingEndMark"> — </span>Semen cryopreservation should be made available to all males diagnosed with testicular cancer prior to instituting therapy if they wish to preserve fertility. If possible, a baseline sperm count and sperm banking should be performed prior to the radiographic diagnostic evaluation in order to avoid radiation exposure of the sperm. (See  <a class="medical medical_review" href="/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p>However, a number of issues need to be considered:</p><p class="bulletIndent1"><span class="glyph">●</span>Testicular tumors are associated with gonadal dysgenesis, and approximately 50 percent of males have some degree of underlying impairment of spermatogenesis [<a href="#rid41">41-47</a>] (see  <a class="medical medical_review" href="/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men", section on 'Testicular cancer'</a>). Semen quality may further deteriorate following removal of the affected testis [<a href="#rid47">47</a>], although others have shown no impact of orchiectomy [<a href="#rid48">48</a>]. The cause of gonadal dysgenesis is unknown in these males; it has been suggested that common etiologic factors are responsible for both low semen quality and testicular cancer [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite this abnormality, sperm from males with testicular cancer does not appear to be more sensitive to the effects of cryopreservation and thawing than normal donors [<a href="#rid45">45</a>]. Males with seminoma may have better sperm quality both before and after cryopreservation than those with nonseminomatous germ cell tumors (NSGCTs) [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Newer assisted reproductive techniques and improvements in cryopreservation techniques may permit successful future pregnancy in 30 to 60 percent of males who undergo treatment for testicular cancer [<a href="#rid51">51-53</a>] (see  <a class="medical medical_review" href="/d/html/7452.html" rel="external">"Treatments for male infertility"</a>). Congenital abnormalities have not been noted in these children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not all males are willing to undergo sperm testing or banking.</p><p></p><p class="headingAnchor" id="H2296861892"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122274.html" rel="external">"Society guideline links: Testicular cancer"</a>.)</p><p class="headingAnchor" id="H201562089"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/863.html" rel="external">"Patient education: Testicular cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Testicular germ cell tumors (GCTs) are the most common malignancies affecting adult males between the ages 15 and 35 years. Testicular GCTs are highly curable cancers. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A majority of patients present with a painless testicular mass. Other less common clinical manifestations include local symptoms (such as pain or a heaviness in the lower abdomen), gynecomastia, or symptoms due to metastases. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The initial diagnostic evaluation of the patient with a suspected testicular tumor should include (see <a class="local">'Diagnostic evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Physical exam and scrotal ultrasound</strong> – Physical examination of the scrotum supplemented by ultrasound to differentiate tumor from a hydrocele or epididymitis. (See <a class="local">'Scrotal ultrasound'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serum tumor markers</strong> – These include the beta subunit of human chorionic gonadotropin [beta-hCG], alpha-fetoprotein [AFP], and lactate dehydrogenase [LDH]). (See <a class="local">'Serum tumor markers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging studies</strong> – Imaging studies should include chest radiograph as well as computed tomography (CT) or magnetic resonance imaging (MRI) of the pelvis and abdomen to look for evidence of regional lymph node metastases. (See <a class="local">'Imaging studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sperm</strong> <strong>cryopreservation </strong>– Prior to definitive treatment, cryopreservation of sperm should be made available to all males who wish to preserve fertility. (See <a class="local">'Cryopreservation of sperm'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Radical inguinal orchiectomy is used both to provide the histologic diagnosis and for local tumor control. Lesser surgical procedures, such as biopsy of the testicle, are generally contraindicated. (See <a class="local">'Radical inguinal orchiectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging </strong>– Tumor staging  (<a class="graphic graphic_table graphicRef110731 graphicRef110732" href="/d/graphic/110731.html" rel="external">table 2A-B</a>) is determined from pathology of the primary tumor, lymphatic spread, the presence or absence of metastases, and the levels of serum beta-hCG, AFP, and LDH. (See <a class="local">'Staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification</strong> – For males with metastatic testicular cancer, males are stratified into separate prognostic groups using the International Germ Cell Cancer Collaborative Group (IGCCCG) stratification system. (See  <a class="medical medical_review" href="/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Definition of risk'</a>.)</p><p></p><p class="headingAnchor" id="H4160560308"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William K Oh, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.</a></li><li class="breakAll">American Cancer Society: Testicular Cancer Survival Rates https://www.cancer.org/cancer/testicular-cancer/detection-diagnosis-staging/survival-rates.html (Accessed on January 19, 2022).</li><li><a class="nounderline abstract_t">Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337:242.</a></li><li><a class="nounderline abstract_t">Tseng A Jr, Horning SJ, Freiha FS, et al. Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications. Cancer 1985; 56:2534.</a></li><li><a class="nounderline abstract_t">Gabrilove JL, Nicolis GL, Mitty HA, Sohval AR. Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature. Cancer 1975; 35:1184.</a></li><li><a class="nounderline abstract_t">Oosting SF, de Haas EC, Links TP, et al. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol 2010; 21:104.</a></li><li><a class="nounderline abstract_t">Voltz R, Gultekin SH, Rosenfeld MR, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340:1788.</a></li><li><a class="nounderline abstract_t">Benson CB. The role of ultrasound in diagnosis and staging of testicular cancer. Semin Urol 1988; 6:189.</a></li><li><a class="nounderline abstract_t">Marth D, Scheidegger J, Studer UE. Ultrasonography of testicular tumors. Urol Int 1990; 45:237.</a></li><li><a class="nounderline abstract_t">Schultz-Lampel D, Bogaert G, Thüroff JW, et al. MRI for evaluation of scrotal pathology. Urol Res 1991; 19:289.</a></li><li><a class="nounderline abstract_t">Toren PJ, Roberts M, Lecker I, et al. Small incidentally discovered testicular masses in infertile men--is active surveillance the new standard of care? J Urol 2010; 183:1373.</a></li><li><a class="nounderline abstract_t">Eifler JB Jr, King P, Schlegel PN. Incidental testicular lesions found during infertility evaluation are usually benign and may be managed conservatively. J Urol 2008; 180:261.</a></li><li><a class="nounderline abstract_t">Powell TM, Tarter TH. Management of nonpalpable incidental testicular masses. J Urol 2006; 176:96.</a></li><li><a class="nounderline abstract_t">Rolle L, Tamagnone A, Destefanis P, et al. Microsurgical "testis-sparing" surgery for nonpalpable hypoechoic testicular lesions. Urology 2006; 68:381.</a></li><li><a class="nounderline abstract_t">Tan IB, Ang KK, Ching BC, et al. Testicular microlithiasis predicts concurrent testicular germ cell tumors and intratubular germ cell neoplasia of unclassified type in adults: a meta-analysis and systematic review. Cancer 2010; 116:4520.</a></li><li><a class="nounderline abstract_t">Trout AT, Chow J, McNamara ER, et al. Association between Testicular Microlithiasis and Testicular Neoplasia: Large Multicenter Study in a Pediatric Population. Radiology 2017; 285:576.</a></li><li><a class="nounderline abstract_t">Richenberg J, Brejt N. Testicular microlithiasis: is there a need for surveillance in the absence of other risk factors? Eur Radiol 2012; 22:2540.</a></li><li><a class="nounderline abstract_t">Costabile RA. How worrisome is testicular microlithiasis? Curr Opin Urol 2007; 17:419.</a></li><li><a class="nounderline abstract_t">Richie JP, Garnick MB, Finberg H. Computerized tomography: how accurate for abdominal staging of testis tumors? J Urol 1982; 127:715.</a></li><li><a class="nounderline abstract_t">Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992; 10:1762.</a></li><li><a class="nounderline abstract_t">Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995; 13:1188.</a></li><li><a class="nounderline abstract_t">Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol 1995; 154:1045.</a></li><li><a class="nounderline abstract_t">Socinski MA, Stomper PC. Radiologic evaluation of nonseminomatous germ cell tumor of the testis. Semin Urol 1988; 6:203.</a></li><li><a class="nounderline abstract_t">Howard SA, Gray KP, O'Donnell EK, et al. Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. AJR Am J Roentgenol 2014; 203:W415.</a></li><li><a class="nounderline abstract_t">de Wit M, Brenner W, Hartmann M, et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 2008; 19:1619.</a></li><li><a class="nounderline abstract_t">Huddart RA, O'Doherty MJ, Padhani A, et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007; 25:3090.</a></li><li class="breakAll">Bower M, Rustin GJ. Serum tumor markers and their role in monitoring germ cell cancers of the testis. In: Textbook of Genitourinary Oncology, 2nd ed, Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (Eds), Lippincott, Williams and Wilkins, Philadelphia 2000. p.931.</li><li><a class="nounderline abstract_t">Regouc M, Belge G, Lorch A, et al. Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer. Cancers (Basel) 2020; 12.</a></li><li><a class="nounderline abstract_t">Grigor KM, Rørth M. Should the contralateral testis be biopsied? Round table discussion. Eur Urol 1993; 23:129.</a></li><li><a class="nounderline abstract_t">Fosså SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005; 97:1056.</a></li><li><a class="nounderline abstract_t">Sharma P, Dhillon J, Sexton WJ. Intratubular Germ Cell Neoplasia of the Testis, Bilateral Testicular Cancer, and Aberrant Histologies. Urol Clin North Am 2015; 42:277.</a></li><li><a class="nounderline abstract_t">Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer: 2015 Update. Eur Urol 2015; 68:1054.</a></li><li class="breakAll">Brimo F, Srigley JR, Ryan CJ, et al. Testis. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), Springer, New York 2017. p.727.</li><li><a class="nounderline abstract_t">Birch R, Williams S, Cone A, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4:400.</a></li><li><a class="nounderline abstract_t">Samuels ML, Johnson DE, Holoye PY. Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother Rep 1975; 59:563.</a></li><li><a class="nounderline abstract_t">Bosl GJ, Geller NL, Cirrincione C, et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983; 43:3403.</a></li><li><a class="nounderline abstract_t">Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995; 13:2255.</a></li><li><a class="nounderline abstract_t">Hoskin P, Dilly S, Easton D, et al. Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 1986; 4:1031.</a></li><li><a class="nounderline abstract_t">International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594.</a></li><li><a class="nounderline abstract_t">Jamal-Hanjani M, Karpathakis A, Kwan A, et al. Bone metastases in germ cell tumours: lessons learnt from a large retrospective study. BJU Int 2013; 112:176.</a></li><li><a class="nounderline abstract_t">Fosså SD, Kravdal O. Fertility in Norwegian testicular cancer patients. Br J Cancer 2000; 82:737.</a></li><li><a class="nounderline abstract_t">Gordon W Jr, Siegmund K, Stanisic TH, et al. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys 1997; 38:83.</a></li><li><a class="nounderline abstract_t">Ohl DA, Sonksen J. What are the chances of infertility and should sperm be banked? Semin Urol Oncol 1996; 14:36.</a></li><li><a class="nounderline abstract_t">Panidis D, Rousso D, Stergiopoulos K, et al. The effect of testicular seminoma in semen quality. Eur J Obstet Gynecol Reprod Biol 1999; 83:219.</a></li><li><a class="nounderline abstract_t">Hallak J, Kolettis PN, Sekhon VS, et al. Sperm cryopreservation in patients with testicular cancer. Urology 1999; 54:894.</a></li><li><a class="nounderline abstract_t">Carroll PR, Whitmore WF Jr, Herr HW, et al. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. J Urol 1987; 137:420.</a></li><li><a class="nounderline abstract_t">Petersen PM, Skakkebaek NE, Rørth M, Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol 1999; 161:822.</a></li><li><a class="nounderline abstract_t">Sibert L, Rives N, Rey D, et al. Semen cryopreservation after orchidectomy in men with testicular cancer. BJU Int 1999; 84:1038.</a></li><li><a class="nounderline abstract_t">Jacobsen R, Bostofte E, Engholm G, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ 2000; 321:789.</a></li><li><a class="nounderline abstract_t">Agarwal A, Tolentino MV Jr, Sidhu RS, et al. Effect of cryopreservation on semen quality in patients with testicular cancer. Urology 1995; 46:382.</a></li><li><a class="nounderline abstract_t">Hartmann JT, Albrecht C, Schmoll HJ, et al. Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 1999; 80:801.</a></li><li><a class="nounderline abstract_t">Turek PJ, Lowther DN, Carroll PR. Fertility issues and their management in men with testis cancer. Urol Clin North Am 1998; 25:517.</a></li><li><a class="nounderline abstract_t">Nalesnik JG, Sabanegh ES Jr, Eng TY, Buchholz TA. Fertility in men after treatment for stage 1 and 2A seminoma. Am J Clin Oncol 2004; 27:584.</a></li></ol></div><div id="topicVersionRevision">Topic 2980 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9227931" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Testicular germ-cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4042075" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Gynecomastia in testicular cancer patients. Prognostic and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1090360" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19605510" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362822" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3072643" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The role of ultrasound in diagnosis and staging of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2163557" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ultrasonography of testicular tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1659016" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : MRI for evaluation of scrotal pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171671" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Small incidentally discovered testicular masses in infertile men--is active surveillance the new standard of care?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499177" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidental testicular lesions found during infertility evaluation are usually benign and may be managed conservatively.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16753377" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Management of nonpalpable incidental testicular masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904457" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Microsurgical "testis-sparing" surgery for nonpalpable hypoechoic testicular lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578177" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Testicular microlithiasis predicts concurrent testicular germ cell tumors and intratubular germ cell neoplasia of unclassified type in adults: a meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28715257" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association between Testicular Microlithiasis and Testicular Neoplasia: Large Multicenter Study in a Pediatric Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22710430" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Testicular microlithiasis: is there a need for surveillance in the absence of other risk factors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17921777" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : How worrisome is testicular microlithiasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7069838" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Computerized tomography: how accurate for abdominal staging of testis tumors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1403057" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7537802" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637051" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3244965" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Radiologic evaluation of nonseminomatous germ cell tumor of the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25247970" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18453520" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634488" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634488" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32235691" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8477772" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Should the contralateral testis be biopsied? Round table discussion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16030303" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26216815" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intratubular Germ Cell Neoplasia of the Testis, Bilateral Testicular Cancer, and Aberrant Histologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26297604" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Guidelines on Testicular Cancer: 2015 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26297604" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Guidelines on Testicular Cancer: 2015 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2419524" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prognostic factors for favorable outcome in disseminated germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/54212" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6850645" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666083" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Stage I testicular seminoma: results of adjuvant irradiation and surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2425060" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9053482" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23795785" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bone metastases in germ cell tumours: lessons learnt from a large retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10682691" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fertility in Norwegian testicular cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9212008" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8833388" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : What are the chances of infertility and should sperm be banked?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391536" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The effect of testicular seminoma in semen quality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10565754" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sperm cryopreservation in patients with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3029434" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Endocrine and exocrine profiles of men with testicular tumors before orchiectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022693" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571631" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Semen cryopreservation after orchidectomy in men with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11009515" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk of testicular cancer in men with abnormal semen characteristics: cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7660514" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effect of cryopreservation on semen quality in patients with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10360658" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term effects on sexual function and fertility after treatment of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728221" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fertility issues and their management in men with testis cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577436" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fertility in men after treatment for stage 1 and 2A seminoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
